G
34.27
0.22 (0.65%)
| Previous Close | 34.05 |
| Open | 34.01 |
| Volume | 3,165,798 |
| Avg. Volume (3M) | 5,396,336 |
| Market Cap | 69,920,055,296 |
| Price / Earnings (TTM) | 23.00 |
| Price / Earnings (Forward) | 8.78 |
| Price / Sales | 1.99 |
| Price / Book | 4.47 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2025 |
| TTM Dividend Yield | 4.54% |
| Profit Margin | 8.21% |
| Operating Margin (TTM) | 12.28% |
| Diluted EPS (TTM) | 1.60 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Quarterly Earnings Growth (YOY) | 18.30% |
| Total Debt/Equity (MRQ) | 129.80% |
| Current Ratio (MRQ) | 0.780 |
| Operating Cash Flow (TTM) | 6.55 B |
| Levered Free Cash Flow (TTM) | 4.90 B |
| Return on Assets (TTM) | 6.53% |
| Return on Equity (TTM) | 22.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Bullish |
| Drug Manufacturers - General (Global) | Bullish | Bullish | |
| Stock | GSK plc | Mixed | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Large Value |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 17.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jtc Employer Solutions Trustee Ltd | 31 Dec 2024 | 20,278,564 |
| Provident Trust Co | 30 Sep 2024 | 3,953,602 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Mar 2025 | Announcement | Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older |
| 17 Feb 2025 | Announcement | PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY |
| 04 Feb 2025 | CNBC | Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
| 27 Jan 2025 | CNBC | Pharma is hopeful about Trump's second term — here's what to expect for drugmakers |
| 17 Jan 2025 | CNBC | Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications |
| 13 Jan 2025 | Announcement | GSK Enters Agreement to Acquire IDRx, Inc. |
| TTM Dividend Yield | 4.54% |
| 3Y Average Dividend Yield | 3.09% |
| Payout Ratio | 97.83% |
| Expected Next Dividend Payment | Apr 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 15 Nov 2024 | 30 Oct 2024 | 09 Jan 2025 | 0.389052 Cash |
| 16 Aug 2024 | 31 Jul 2024 | 10 Oct 2024 | 0.385671 Cash |
| 16 May 2024 | 01 May 2024 | 11 Jul 2024 | 0.376185 Cash |
| 22 Feb 2024 | 01 Feb 2024 | 11 Apr 2024 | 0.4060608 Cash |
| 16 Nov 2023 | 01 Nov 2023 | 11 Jan 2024 | 0.3397772 Cash |
| 17 Aug 2023 | 26 Jul 2023 | 12 Oct 2023 | 0.361256 Cash |
| 18 May 2023 | 26 Apr 2023 | 13 Jul 2023 | 0.347508 Cash |
| 23 Feb 2023 | 01 Feb 2023 | 13 Apr 2023 | 0.3403867 Cash |
| 17 Nov 2022 | 02 Nov 2022 | 12 Jan 2023 | 0.3171217 Cash |
| 18 Aug 2022 | 27 Jul 2022 | 06 Oct 2022 | 0.390832 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.389 | 1 | 1.14 |
| 2024 | 1.51 | 4 | 4.46 |
| 2023 | 1.37 | 4 | 3.69 |
| 2022 | 0.391 | 1 | 1.11 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |